Sofosbuvir for treating chronic hepatitis C

  • Technology appraisal guidance
  • TA330
  • Published: 
Download guidance (PDF)

9 Sources of evidence considered by the Committee.

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Southampton Health Technology Assessment Centre:

  • Copley V, Frampton G, Pickett K, et al. Sofosbuvir for treating chronic hepatitis C, April 2014

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to make written submissions. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Company:

  • Gilead Sciences

II. Professional/expert and patient/carer groups:

  • British Liver Trust

  • Liver4Life

  • The Hepatitis C Trust

  • HIV i‑Base

  • British Association for Sexual Health and HIV

  • British Association for Study of the Liver

  • British Association for the Study of the Liver Nurses Forum

  • British HIV Association

  • British Society of Gastroenterology

  • Royal College of General Practitioners

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

  • United Kingdom Clinical Pharmacy Association

III. Other consultees:

  • Department of Health

  • NHS Bromley CCG

  • NHS England

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety, Northern Ireland

  • Healthcare Improvement Scotland

  • Janssen

  • Merck Sharp & Dohme

  • Roche Products

  • Centre for Sexual Health & HIV Research

  • Foundation for Liver Research

  • MRC Clinical Trials Unit

  • National Institute for Health Research Health Technology Assessment Programme

  • Southampton Health Assessment Centre

  • National Clinical Guideline Centre

  • Public Health England

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on sofosbuvir by attending the initial Committee discussion and providing a written statement to the Committee. They were invited to comment on the ACD.

  • Dr Richard Aspinall, Consultant Hepatologist, nominated by the British Society of Gastroenterology – clinical expert

  • Dr Michael Jacobs, Consultant in Infectious Diseases, nominated by the Royal College of Physicians – clinical expert

  • Mr Charles Gore, Chief Executive of the Hepatitis C Trust, nominated by the Hepatitis C Trust – patient expert

  • Mr Andrew Zapletal, nominated by the Hepatitis C Trust – patient expert

D. The following individuals were nominated as NHS commissioning experts by NHS England. They gave their expert/NHS commissioning personal view on sofosbuvir by attending the initial Committee discussion and providing a written statement to the Committee. They were invited to comment on the ACD.

  • Ms Adele Torkington, selected by NHS England – NHS Commissioning expert

E. Representatives from the following company attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Gilead Sciences

  • National Institute for Health and Care Excellence (NICE)